Sarepta Therapeutics (NASDAQ:SRPT) Price Target Raised to $235.00 at Needham & Company LLC

Sarepta Therapeutics (NASDAQ:SRPT) had its price target increased by Needham & Company LLC from $166.00 to $235.00 in a report released on Friday, Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

A number of other research analysts also recently weighed in on SRPT. Piper Sandler assumed coverage on Sarepta Therapeutics in a research note on Friday, May 31st. They set an overweight rating and a $157.00 price target on the stock. Bank of America upped their price target on Sarepta Therapeutics from $166.00 to $213.00 and gave the stock a buy rating in a research note on Friday. Citigroup upped their price target on Sarepta Therapeutics from $160.00 to $172.00 and gave the stock a buy rating in a research note on Thursday, February 29th. Cantor Fitzgerald reissued a neutral rating and set a $128.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, May 2nd. Finally, BMO Capital Markets reissued an outperform rating and set a $170.00 price objective on shares of Sarepta Therapeutics in a report on Friday, June 14th. Four research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of Moderate Buy and an average price target of $177.65.

Sarepta Therapeutics Stock Up 30.1 %

Shares of NASDAQ:SRPT opened at $160.72 on Friday. The company has a market capitalization of $15.19 billion, a price-to-earnings ratio of 1,461.09 and a beta of 0.96. The company has a debt-to-equity ratio of 1.18, a current ratio of 4.05 and a quick ratio of 3.44. The business’s 50-day moving average is $125.56 and its 200-day moving average is $119.73. Sarepta Therapeutics has a 1 year low of $55.25 and a 1 year high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.84. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. The business had revenue of $413.50 million for the quarter, compared to the consensus estimate of $375.52 million. During the same period in the prior year, the business earned ($1.44) EPS. The firm’s revenue for the quarter was up 63.1% on a year-over-year basis. Equities research analysts predict that Sarepta Therapeutics will post 2.99 earnings per share for the current year.

Insider Activity

In other Sarepta Therapeutics news, insider Dallan Murray sold 3,635 shares of the stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $140.00, for a total transaction of $508,900.00. Following the completion of the transaction, the insider now directly owns 18,125 shares of the company’s stock, valued at $2,537,500. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 7.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Sarepta Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in Sarepta Therapeutics by 2.8% during the fourth quarter. Vanguard Group Inc. now owns 8,816,124 shares of the biotechnology company’s stock valued at $850,139,000 after purchasing an additional 243,180 shares during the period. Capital International Investors grew its holdings in Sarepta Therapeutics by 1.6% during the first quarter. Capital International Investors now owns 4,817,517 shares of the biotechnology company’s stock valued at $623,676,000 after purchasing an additional 76,032 shares during the period. Avoro Capital Advisors LLC lifted its position in shares of Sarepta Therapeutics by 7.9% during the fourth quarter. Avoro Capital Advisors LLC now owns 4,344,444 shares of the biotechnology company’s stock worth $418,935,000 after acquiring an additional 319,444 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Sarepta Therapeutics by 5.6% during the fourth quarter. Wellington Management Group LLP now owns 4,127,610 shares of the biotechnology company’s stock worth $398,025,000 after acquiring an additional 217,810 shares in the last quarter. Finally, Farallon Capital Management LLC lifted its position in shares of Sarepta Therapeutics by 102.8% during the first quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock worth $317,630,000 after acquiring an additional 1,243,427 shares in the last quarter. 86.68% of the stock is owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.